Treatment of growth-hormone deficiency with growth-hormone-releasing hormone

GHRH(1-29)NH2 increased height velocity in 12 of 18 GH-deficient children, with 8 showing sustained worthwhile response over 6-18 months of twice-daily injections.

Abstract

18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2.. In 12 of the children the height velocity rose on GHRH treatment, and 8 were judged to have shown a worthwhile response to therapy in that their height velocities during the first 6 months of treatment increased by greater.

Key Findings

In 12 of the children the height velocity rose on GHRH treatment, and 8 were judged to have shown a worthwhile response to therapy in that their height velocities during the first 6 months of treatmen... | These 8 children have now been treated for 6 to 18 months and their increase in height velocity has been maintained. | 4 of these patients showed growth deceleration with GHRH, for unknown reasons.

Study Design

Clinical study